These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 36368321)

  • 1. Cancer-selective metabolic vulnerabilities in MYC-amplified medulloblastoma.
    Gwynne WD; Suk Y; Custers S; Mikolajewicz N; Chan JK; Zador Z; Chafe SC; Zhai K; Escudero L; Zhang C; Zaslaver O; Chokshi C; Shaikh MV; Bakhshinyan D; Burns I; Chaudhry I; Nachmani O; Mobilio D; Maich WT; Mero P; Brown KR; Quaile AT; Venugopal C; Moffat J; Montenegro-Burke JR; Singh SK
    Cancer Cell; 2022 Dec; 40(12):1488-1502.e7. PubMed ID: 36368321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of protein arginine methyltransferase 5 in group 3 (MYC-driven) Medulloblastoma.
    Chaturvedi NK; Mahapatra S; Kesherwani V; Kling MJ; Shukla M; Ray S; Kanchan R; Perumal N; McGuire TR; Sharp JG; Joshi SS; Coulter DW
    BMC Cancer; 2019 Nov; 19(1):1056. PubMed ID: 31694585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic activity of BET inhibitor MK-8628 and PLK inhibitor Volasertib in preclinical models of medulloblastoma.
    Han Y; Lindner S; Bei Y; Garcia HD; Timme N; Althoff K; Odersky A; Schramm A; Lissat A; Künkele A; Deubzer HE; Eggert A; Schulte JH; Henssen AG
    Cancer Lett; 2019 Mar; 445():24-33. PubMed ID: 30611741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Novel Combination Approach Targeting an Enhanced Protein Synthesis Pathway in MYC-driven (Group 3) Medulloblastoma.
    Chaturvedi NK; Kling MJ; Griggs CN; Kesherwani V; Shukla M; McIntyre EM; Ray S; Liu Y; McGuire TR; Sharp JG; Band H; Joshi SS; Coulter DW
    Mol Cancer Ther; 2020 Jun; 19(6):1351-1362. PubMed ID: 32371591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Class I HDAC inhibition reduces DNA damage repair capacity of MYC-amplified medulloblastoma cells.
    Vollmer J; Ecker J; Hielscher T; Valinciute G; Ridinger J; Jamaladdin N; Peterziel H; van Tilburg CM; Oehme I; Witt O; Milde T
    J Neurooncol; 2023 Sep; 164(3):617-632. PubMed ID: 37783879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EYA2 tyrosine phosphatase inhibition reduces MYC and prevents medulloblastoma progression.
    Wolin AR; Vincent MY; Hotz T; Purdy SC; Rosenbaum SR; Hughes CJ; Hsu JY; Oliphant MUJ; Armstrong B; Wessells V; Varella-Garcia M; Galbraith MD; Pierce A; Wang D; Venkataraman S; Danis E; Veo B; Serkova N; Espinosa JM; Gustafson DL; Vibhakar R; Ford HL
    Neuro Oncol; 2023 Dec; 25(12):2287-2301. PubMed ID: 37486991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic targeting of both dihydroorotate dehydrogenase and nucleoside transport in MYCN-amplified neuroblastoma.
    Yu Y; Ding J; Zhu S; Alptekin A; Dong Z; Yan C; Zha Y; Ding HF
    Cell Death Dis; 2021 Aug; 12(9):821. PubMed ID: 34462431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. OLIG2 Is a Determinant for the Relapse of MYC-Amplified Medulloblastoma.
    Xu Z; Murad N; Malawsky D; Tao R; Rivero-Hinojosa S; Holdhof D; Schüller U; Zhang P; Lazarski C; Rood BR; Packer R; Gershon T; Pei Y
    Clin Cancer Res; 2022 Oct; 28(19):4278-4291. PubMed ID: 35736214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination drug screen identifies synergistic drug interaction of BCL-XL and class I histone deacetylase inhibitors in MYC-amplified medulloblastoma cells.
    Zeuner S; Vollmer J; Sigaud R; Oppermann S; Peterziel H; ElHarouni D; Oehme I; Witt O; Milde T; Ecker J
    J Neurooncol; 2024 Jan; 166(1):99-112. PubMed ID: 38184819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma.
    Kling MJ; Kesherwani V; Mishra NK; Alexander G; McIntyre EM; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
    J Exp Clin Cancer Res; 2022 Nov; 41(1):321. PubMed ID: 36357906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triptolide and its prodrug Minnelide target high-risk MYC-amplified medulloblastoma in preclinical models.
    Rodriguez-Blanco J; Salvador AD; Suter RK; Swiderska-Syn M; Palomo-Caturla I; Kliebe V; Shahani P; Peterson K; Turos-Cabal M; Vieira ME; Wynn DT; Howell AJ; Yang F; Ban Y; McCrea HJ; Zindy F; Danis E; Vibhakar R; Jermakowicz A; Martin V; Coss CC; Harris BT; de Cubas A; Chen XS; Barnoud T; Roussel MF; Ayad NG; Robbins DJ
    J Clin Invest; 2024 Jun; 134(15):. PubMed ID: 38885332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BET bromodomain protein inhibition is a therapeutic option for medulloblastoma.
    Henssen A; Thor T; Odersky A; Heukamp L; El-Hindy N; Beckers A; Speleman F; Althoff K; Schäfers S; Schramm A; Sure U; Fleischhack G; Eggert A; Schulte JH
    Oncotarget; 2013 Nov; 4(11):2080-95. PubMed ID: 24231268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Marinopyrrole derivative MP1 as a novel anti-cancer agent in group 3 MYC-amplified Medulloblastoma.
    Coulter DW; Chhonker YS; Kumar D; Kesherwani V; Aldhafiri WN; McIntyre EM; Alexander G; Ray S; Joshi SS; Li R; Murry DJ; Chaturvedi NK
    J Exp Clin Cancer Res; 2024 Jan; 43(1):18. PubMed ID: 38200580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with In Silico Analysis to Identify Novel Therapeutic Targets.
    Hanaford AR; Archer TC; Price A; Kahlert UD; Maciaczyk J; Nikkhah G; Kim JW; Ehrenberger T; Clemons PA; Dančík V; Seashore-Ludlow B; Viswanathan V; Stewart ML; Rees MG; Shamji A; Schreiber S; Fraenkel E; Pomeroy SL; Mesirov JP; Tamayo P; Eberhart CG; Raabe EH
    Clin Cancer Res; 2016 Aug; 22(15):3903-14. PubMed ID: 27012813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting MYC-driven replication stress in medulloblastoma with AZD1775 and gemcitabine.
    Moreira DC; Venkataraman S; Subramanian A; Desisto J; Balakrishnan I; Prince E; Pierce A; Griesinger A; Green A; Eberhardt CG; Foreman NK; Vibhakar R
    J Neurooncol; 2020 May; 147(3):531-545. PubMed ID: 32180106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma.
    Bolin S; Borgenvik A; Persson CU; Sundström A; Qi J; Bradner JE; Weiss WA; Cho YJ; Weishaupt H; Swartling FJ
    Oncogene; 2018 May; 37(21):2850-2862. PubMed ID: 29511348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of the de novo pyrimidine biosynthesis pathway limits ribosomal RNA transcription causing nucleolar stress in glioblastoma cells.
    Lafita-Navarro MC; Venkateswaran N; Kilgore JA; Kanji S; Han J; Barnes S; Williams NS; Buszczak M; Burma S; Conacci-Sorrell M
    PLoS Genet; 2020 Nov; 16(11):e1009117. PubMed ID: 33201894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular and functional profiling of chemotolerant cells unveils nucleoside metabolism-dependent vulnerabilities in medulloblastoma.
    Mariotto E; Rampazzo E; Bortolozzi R; Rruga F; Zeni I; Manfreda L; Marchioro C; Canton M; Cani A; Magni R; Luchini A; Bresolin S; Viola G; Persano L
    Acta Neuropathol Commun; 2023 Nov; 11(1):183. PubMed ID: 37978570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammation.
    Marquardt V; Theruvath J; Pauck D; Picard D; Qin N; Blümel L; Maue M; Bartl J; Ahmadov U; Langini M; Meyer FD; Cole A; Cruz-Cruz J; Graef CM; Wölfl M; Milde T; Witt O; Erdreich-Epstein A; Leprivier G; Kahlert U; Stefanski A; Stühler K; Keir ST; Bigner DD; Hauer J; Beez T; Knobbe-Thomsen CB; Fischer U; Felsberg J; Hansen FK; Vibhakar R; Venkatraman S; Cheshier SH; Reifenberger G; Borkhardt A; Kurz T; Remke M; Mitra S
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36639156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. c-MYC expression sensitizes medulloblastoma cells to radio- and chemotherapy and has no impact on response in medulloblastoma patients.
    von Bueren AO; Oehler C; Shalaby T; von Hoff K; Pruschy M; Seifert B; Gerber NU; Warmuth-Metz M; Stearns D; Eberhart CG; Kortmann RD; Rutkowski S; Grotzer MA
    BMC Cancer; 2011 Feb; 11():74. PubMed ID: 21324178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.